Journal
Discover Oncology
Discover Oncology is an open access journal publishing content that interfaces at all levels of cancer research.
In the pursuit of breaking through the basement membrane and invading the vasculature, neoplastic cells go through a complex process called as metastasis which is dependent on a plethora of factors such as proliferation, survival, vascularization etc. Subsequent to the logistics in the circulation, the tumor cells extravasate to secondary sites which involve a cascade of events and factors. These steps are highly rate limiting and might offer the opportunity for testing any possible therapeutics.
There is a rising acknowledgement that initiation of epithelial-mesenchymal transition, which is the prequel of metastasis, entails loss of cell adhesion, activation of several transcription factors, enzymes etc. EMT further triggers a change in characteristic morphology, gene expression of epithelial cells and so on. Additionally, there are several biomarkers that have been found to be instrumental in EMT and cancer progression such as EMT genes, MMPs, transcription factors etc. Overall, exploring these biomarkers and factors would be utmost essential in unravelling cancer therapy. Technology is constantly evolving which is bringing us various platforms to study and understand metastasis such as two-dimensional tumor matrix adhesion assays, organoids, cell migration assays, 2D and 3D substrate assays, cell exclusion zone assays, microfluidic assays, lab on chip assays, biomimetic synthetic matrices etc. It would be really interesting to investigate the pros and cons of these assays in exploring metastatic cascades.
The current special Collection would therefore cover multidimensional aspects about metastasis and EMT right from mechanisms to therapeutics and from in vitro to in vivo. The Collection would predominantly cover aspects such as:
• State of art reviews covering metastatic mechanisms.
• Novel experimental therapeutics.
• New findings and clinical studies and case studies pertaining to EMT and metastasis.
Keywords: cancer migration, metastasis, EMT, cancer therapeutics
Submit your manuscript to this collection through the participating journal.
-
Rohit Gundamaraju
PhD, University of Tasmania, Australia.Dr. Rohit Gundamaraju is an accomplished scientist in the field of cancer biology with a special interest and expertise in solid tumors. He obtained his doctoral disease in gastrointestinal cancers from the University of Tasmania, Australia. His postdoctoral training was on diverse carcinomas. During his research and training, he has published important works related to cancer therapeutics and translational research.